A randomised, double-blind, placebo-controlled, ascending dose Phase I/IIa study to evaluate the safety, tolerability and efficacy of topical LTX-109 in subjects nasally colonized with methicillin-res...

Mise à jour : Il y a 5 ans
Référence : EUCTR2010-019254-40

A randomised, double-blind, placebo-controlled, ascending dose Phase I/IIa study to evaluate the safety, tolerability and efficacy of topical LTX-109 in subjects nasally colonized with methicillin-resistant/-sensitive Staphylococcus aureus (MRSA/MSSA)

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To determine: • Safety and tolerability of LTX-109 when applied topically to the anterior nares three times daily for three days. • Decolonization, eradication or no eradication of nasal MRSA/MSSA after treatment with LTX-109 over a period of three days • The extent of systemic absorption of LTX-109 after application to the anterior nares.


Critère d'inclusion

  • Nasal decolonization of MRSA/MSSA

Liens